Companies › Keros Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KER-065 Activin type IIB receptor (ActR2B) ligand trap; inhibits myostatin and ActA signaling | ACVR2B | Phase 2 | Duchenne Muscular Dystrophy | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07704099 | KER-065 | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Aug 2028 |
Cash of $259m on 2026-09-30; operating cash outflow about $28m a year; runway about 113 months at that burn, to Feb 2036; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Abcuro Tiziana Life Sciences Acumen Pharmaceuticals Bright Minds Biosciences Dianthus Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.